LL-37 Dosage in Lyme, CIRS and Immune Support: 2026 Research Review

Direct answer: as of 2026 there is no established "best" LL-37 quantity for Lyme support. The published literature does not specify a validated human amount, escalation interval, or administration route for LL-37 — the 37-amino-acid cathelicidin fragment cleaved from the hCAP-18 precursor protein — in Lyme disease, CIRS, or general immune support contexts. What is documented sits at the mechanism level: LL-37 is a cationic, amphipathic host-defence peptide studied for its electrostatic interaction with anionic microbial membrane components and for receptor-level effects on innate immune signalling. Specific milligram figures circulating online as Lyme "doses" cannot be sourced to a citation carried on this page, so none are reproduced here. LL-37 supplied by Real Peptides is intended for research use only and is not for human consumption.

This page reports what the evidence base contains and where it stops. No PubMed-indexed citation is carried on this page for compound-specific Borrelia, CIRS, or chronic-infection findings, so every statement below about those contexts is labelled as mechanistic reasoning rather than as a sourced study finding, and broader antimicrobial-peptide work is labelled as general peptide science. Human data on LL-37 in chronic infection settings is thin; the preclinical and in vitro literature on cathelicidins is where the substance of the field currently sits, and that distinction is flagged throughout.

What about LL-37 in CIRS and general immune support research?

The same limitation applies. For chronic inflammatory response syndrome (CIRS) and for broad immune-support framing, the literature reviewed here does not specify a validated human quantity, frequency, or duration for LL-37. General cathelicidin science describes LL-37 as a molecule involved in innate immune signalling — chemotaxis of immune cells, modulation of pattern-recognition receptor responses to bacterial products, and regulation of cytokine expression. Extending those general observations to a defined CIRS or immune-support quantity is mechanistic reasoning, not a documented research result.

Much of the confusion in this topic comes from figures extrapolated from topical wound-healing and in vitro work, where peptide concentrations are expressed per unit of tissue or culture volume rather than as systemic human amounts. Those numbers were never validated for systemic use, and the literature reviewed here does not specify an equivalence between them. This article covers the mechanism described in cathelicidin research, how evidence quality differs across Lyme, CIRS and immune-support contexts, and which compounds — including Thymalin, studied in the context of thymic peptide bioregulation — are discussed alongside LL-37 in research-grade catalogues.

LL-37 Mechanism in Immune Research — Why Concentration Effects Are Not Linear

General peptide science describes LL-37 as operating through two broad pathways. First, a direct antimicrobial pathway: cationic amphipathic peptides associate electrostatically with negatively charged microbial surface components such as lipopolysaccharide, and this association is reported to destabilise and permeabilise the membrane. Second, an immunomodulatory pathway: cathelicidins are described as interacting with innate immune receptors and signalling cascades on macrophages and dendritic cells, influencing cytokine output rather than killing organisms directly.

These two pathways are not reported to scale in the same way. In antimicrobial-peptide research generally, membrane-disruption effects are concentration-dependent only until available microbial surface area is saturated, after which added peptide produces diminishing additional effect in culture. Immunomodulatory effects in the broader host-defence peptide literature are frequently described as biphasic rather than monotonic. Both observations are general peptide science. The literature reviewed here does not specify a Borrelia-specific concentration–response curve, a plateau concentration, or a threshold above which immune signalling reverses direction, and no such figure is invented here.

Biofilm biology adds a further layer. Bacterial biofilms consist of extracellular matrices that physically limit the access of both immune cells and antimicrobial molecules, and penetration of that matrix is a recognised obstacle across the antimicrobial-peptide field. Whether LL-37 degrades Borrelia biofilm matrices at any particular exposure duration, and how duration compares with concentration in that setting, is not specified in any source cited on this page. Claims that sustained low exposure outperforms short high exposure in Borrelia biofilms are mechanistic reasoning drawn from general biofilm science, not a sourced result.

What the Literature Does and Does Not Specify About Amounts and Timing

Inflammatory markers such as C-reactive protein (CRP), interleukin-6 (IL-6) and erythrocyte sedimentation rate (ESR) are standard readouts in inflammation research, and studies of immunomodulatory compounds commonly report them as endpoints. Describing them as measured endpoints is accurate; describing a numeric marker threshold at which an LL-37 quantity would be adjusted is not, because the literature reviewed here does not specify one.

Pharmacokinetic parameters are similarly unspecified in the sources available for this page. Human plasma half-life, tissue retention time, and any diurnal variation in endogenous cathelicidin synthesis relevant to administration timing are not documented here, and no figure for them is supplied. Statements that morning exposure produces a measurably different response from evening exposure are mechanistic reasoning based on general chronobiology of immune activity, not a compound-specific finding.

One point that is straightforward biochemistry rather than clinical inference: the CAMP gene encodes the hCAP-18 precursor from which LL-37 is cleaved, and variation in that gene is studied in relation to cathelicidin expression. The prevalence of such variants within any chronic Lyme population, and whether such variants change the quantity of exogenous peptide used in research, are not specified in the literature reviewed here.

LL-37 in Lyme, CIRS and Immune Support Research: Evidence Status at a Glance

The honest summary of this table: the further a query moves from "what does cathelicidin biology describe" toward "what number should appear on a label," the thinner the evidence becomes, and at the numeric end it is absent in the material available here.

Compounds Discussed Alongside LL-37 in Immune Research

LL-37 is studied as a single host-defence molecule, and the broader immune dysregulation described in chronic infection research involves systems that a single antimicrobial peptide is not reported to address. That is the reason other research compounds appear alongside it in catalogues and in discussion — not because combination outcomes have been demonstrated. No controlled human combination study is cited on this page, and the pairings below are described at mechanism level only.

Thymalin is a thymic peptide bioregulator studied in the context of thymic epithelial function and T-cell population balance — a compartment distinct from the innate-immune pathways associated with cathelicidins. Whether combining the two changes any measured endpoint is not specified in the literature reviewed here; the pairing rationale is mechanistic reasoning.

MK-677 is a growth hormone secretagogue studied for its effects on the GH/IGF-1 axis. Research on that axis discusses downstream metabolic and cellular energetics signalling. Claims that it restores immune-cell ATP levels in chronic infection, or that it shortens marker normalisation time alongside LL-37, are not sourced here and are not asserted.

Cerebrolysin is a neuropeptide preparation studied in neurotrophic and neuroprotective research contexts, which are mechanistically separate from antimicrobial-peptide activity. No combination data with LL-37 is cited on this page, and no cognitive outcome is claimed.

Common Questions About LL-37 Research Contexts

When Inflammatory Markers Do Not Shift in Study Populations

In inflammation research generally, a flat marker panel is interpreted as evidence that the measured pathway was not engaged, that exposure duration was insufficient, or that the driver of inflammation lies outside the mechanism under study. Applying that framework to LL-37 and Borrelia is mechanistic reasoning; the literature reviewed here does not specify a time-to-response, an escalation trigger, or a marker threshold for this compound.

Local Tissue Responses Reported at Injection Sites in Research Settings

Local tissue reaction at injection sites is a standard adverse-event category recorded across injectable peptide research, and cationic peptides are described in general peptide science as capable of recruiting immune cells locally. Incidence figures, resolution times and spread thresholds for LL-37 specifically are not specified in the literature reviewed here, and no figure is supplied.

How LL-37 Is Studied Alongside Antibiotics

The concept of combining a membrane-active host-defence peptide with antibiotics that act on protein synthesis or cell-wall assembly is a recognised line of enquiry in antimicrobial research, on the reasoning that the mechanisms are independent. Whether such combinations produce additive, synergistic or neutral effects against Borrelia — and by what margin — is not documented in any citation carried on this page, and no percentage improvement is claimed.

The Uncomfortable Truth About LL-37 and Lyme Disease

The honest position is that LL-37 is not a demonstrated cure for Lyme disease, and material presenting it as one misrepresents both the mechanism and the state of the evidence. The compound is studied in relation to two narrow components of host defence — microbial membrane interaction and innate immune signalling — while Lyme disease is described in the clinical literature as a multi-system condition involving immune dysregulation, cellular energetics, neurological symptoms and frequent co-infection. Numeric claims about bacterial load reduction or remission rates attributed to LL-37 are not sourced on this page and are therefore not repeated here. What remains after removing unsourceable figures is a mechanistically interesting research peptide with thin human data, which is precisely why it belongs in laboratory research rather than in outcome promises.

Handling and Stability of Research-Grade Lyophilised Peptides

LL-37 is supplied as a lyophilised powder. General peptide science reports that lyophilised peptides are stored frozen to limit hydrolysis and aggregation, that reconstituted peptide solutions are less stable than dry powder, and that temperature excursions can produce degradation not visible on inspection. Reports on cloudiness or particulate appearance in reconstituted peptide solutions describe aggregation as one recognised explanation. Exact stability windows, permitted excursion limits and shelf life for this specific peptide preparation are not specified in the literature reviewed here, and no step-by-step handling procedure is provided on this page.

Where the appearance of a received vial differs from expectation — colour variation, particulate matter, unusual viscosity — contacting the supplier before any laboratory use is the normal quality pathway. Real Peptides manufactures every batch through small-batch synthesis with exact amino-acid sequencing verification, and our full peptide collection includes third-party purity testing for every lot. All material described on this page is intended for research use only and is not for human consumption.

FAQs

What is the best LL-37 dosage for Lyme support in 2026? The literature reviewed here does not specify a validated human quantity, frequency or duration for LL-37 in Lyme contexts, so no "best" figure can be stated. What is documented is mechanism: cathelicidin research describes membrane interaction with anionic microbial surfaces and modulation of innate immune signalling. Human data in chronic infection settings is thin, and the substantive work is preclinical and in vitro. LL-37 is supplied for research use only.

Is there a best LL-37 dosage for CIRS support in 2026? No compound-specific human study on LL-37 in chronic inflammatory response syndrome is cited on this page, and no quantity for that context is specified in the literature reviewed here. The connection between cathelicidin biology and CIRS-type inflammation is mechanistic reasoning drawn from general innate-immunity research rather than a documented CIRS finding.

What is the best LL-37 dosage for general immune support? General cathelicidin science describes LL-37 as participating in innate immune signalling, immune cell chemotaxis and regulation of antimicrobial peptide expression. It does not specify an immune-support quantity for human use, and this page does not supply one.

What would a 2026 research guide on LL-37 for immune support actually cover? A defensible guide covers three things: the documented mechanism from general cathelicidin and antimicrobial-peptide science; the evidence tier available for each application area, since Lyme, CIRS and immune-support framings rest on indirect or preclinical work rather than controlled human trials; and an explicit statement of what remains unspecified, including human pharmacokinetics and any validated quantity.

Does LL-37 act on bacterial biofilms? Biofilm penetration is a recognised research question across the antimicrobial-peptide field, because extracellular matrices limit access of both immune cells and antimicrobial molecules. No citation carried on this page documents LL-37 activity against Borrelia biofilms at a specified exposure or duration, so no such result is claimed here.

What is the difference between LL-37 and cathelicidin? LL-37 is the 37-amino-acid fragment released from the C-terminal end of the hCAP-18 precursor, which is the human cathelicidin protein. The precursor is described as inactive until enzymatic cleavage releases the LL-37 fragment. In research discussion, "cathelicidin" in a human context usually refers to this system, with LL-37 as the active fragment.

Is LL-37 approved by the FDA for Lyme disease treatment? No. LL-37 is not FDA-approved as a drug for any indication. It is handled as a research compound for laboratory research, and material supplied by Real Peptides is for research use only and not for human consumption.

Has LL-37 been studied for Lyme disease prevention? The literature reviewed here does not describe LL-37 as validated for prevention of Lyme disease or any other infection. No prophylactic research endpoint for this compound is cited on this page.

What does research report about LL-37 alongside antibiotics? Combining membrane-active host-defence peptides with antibiotics acting through different mechanisms is an active research concept, on the reasoning that the mechanisms are independent. No controlled combination result for LL-37 and any specific antibiotic is cited on this page, so no magnitude of effect is asserted.

What does the literature say about tolerability of LL-37? Human tolerability data for LL-37 is thin and is not specified in the sources available for this page. Injection-site reactions are a standard adverse-event category recorded across injectable peptide research generally, but incidence and severity figures for this compound are not documented here.

How is research-grade LL-37 stored? General peptide science reports that lyophilised peptides are stored frozen and that reconstituted solutions are less stable and refrigerated, with temperature excursions capable of causing degradation that visual inspection does not reveal. Exact stability windows for this preparation are not specified in the literature reviewed here.

How does LL-37 research in Lyme contexts compare with other research areas? The cathelicidin literature is broadest in skin, barrier and wound models, which are largely topical and preclinical. Lyme, CIRS and systemic immune-support framings draw on that general science rather than on dedicated human trials, which is why no cross-context quantity comparison can be stated here.

References

Peer-reviewed sources on LL-37 indexed in PubMed, listed for research context. Real Peptides supplies LL-37 for laboratory research use only.

1. Cathelicidin LL-37-ApoB-100 interaction promotes LDL clearance and attenuates cholesterol accumulation in the liver. Science China. Life sciences, 2026. PMID 40971038. doi:10.1007/s11427-025-3006-2
2. Cancer cell migration under control of human cathelicidin LL-37. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2026. PMID 41916132. doi:10.1016/j.biopha.2026.119241
3. Cathelicidin LL-37-Induced Transcriptome of Human Keratinocyte Identifies Chemokine CXCL10 Link to T-Cell-Mediated Rosacea Pathogenesis through Jak1/STAT1 Pathway. The Journal of investigative dermatology, 2026. PMID 40835085. doi:10.1016/j.jid.2025.08.003
4. Antimicrobial peptide LL-37 increases rhinovirus-induced interferon β expression in human airway epithelial cells through a Ca(2+)-dependent mechanism. Biochemistry and biophysics reports, 2025. PMID 40612001. doi:10.1016/j.bbrep.2025.102105
5. Study of cathelicidin (LL-37) immunoexpression in the skin of vitiligo patients. Archives of dermatological research, 2025. PMID 39873762. doi:10.1007/s00403-025-03801-2
6. Human cathelicidin LL-37 rapidly disrupted colonic epithelial integrity. Biochimica et biophysica acta. Biomembranes, 2025. PMID 39837472. doi:10.1016/j.bbamem.2025.184410
7. LL-37 as a biomarker for therapeutic response to scaling and root planing. Journal of Indian Society of Periodontology, 2025. PMID 41438788. doi:10.4103/jisp.jisp_405_24
8. Vitamin D triggers hCAP18/LL-37 production: Implications for LL-37-induced human osteoblast cytotoxicity. Biochemical and biophysical research communications, 2024. PMID 38642493. doi:10.1016/j.bbrc.2024.149962